• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Roche Holding AG ADR

Roche Holding AG ADR

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Genentech Provides Update on Phase III Study of Gazyva® in People With Previously Untreated Diffuse Large B-Cell Lymphoma

    Genentech Provides Update on Phase III Study of Gazyva® in People With Previously Untreated Diffuse Large B-Cell Lymphoma

  2. FDA Grants Priority Review for Genentech’s OCREVUS™ (ocrelizumab) Biologics License Application

    FDA Grants Priority Review for Genentech’s OCREVUS™ (ocrelizumab) Biologics License Application

  3. A Push-Me, Pull-You Market

    Maxygen MAXY announced that its partner Roche RHHBY placed a hold on development of Maxy-Alpha--the first of Maxygen's shuffled proteins to enter clinical development--and we're lowering our fair value estimate accordingly. While we had only placed a 20% probability on the eventual approval of ...

  4. Low-Cost Exposure to U.S. Healthcare Firms

    This ETF holds a swath of large- and mid-cap U.S. healthcare companies.

  5. Ariel Goes Abroad

    Ariel International marks the firm’s first foray into foreign-stock investing. It has been a performance success so far.

  6. Roche Builds a Wide Moat With Dominant Oncology and Diagnostics Franchises

    Firm has a promising strategy of combining expertise in both areas to generate a growing personalized medicine pipeline.

  7. 4 Companies Leading the Next Wave of Cancer-Drug Innovation

    First movers and firms that provide combination therapies represent the best investment opportunities in the immuno-oncology market, says Morningstar's Damien Conover.

  8. The Ultimate Stock-Pickers’ Top 10 Dividend Stocks

    Top managers continue to focus on higher-quality dividend-paying stocks in a fully valued market.

  9. Why Retirees Should Consider Investing Abroad

    Readers say diversification and exposure to good companies call for looking beyond the U.S.

  10. Actavis' Wide-Moat Transformation Offers Shareholder Rewards

    Product durability, diversification, and cost synergies support strong earnings growth for this undervalued wide-moat firm.

1234
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.